853685-38-8

Upstream product

• 17288-32-3 1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid ethyl ester 
• 64362-41-0 diethyl 2-(3-nitropyridin-2-yl)malonate 
• 23596-34-1 2-hydroxy-3-(3-nitropyridin-2-yl)acrylic acid ethyl ester 
• 853685-35-5 1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide 
• 63930-17-6 1,2-di(m-tolyl)disulfane 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 18699-87-1 2-methyl-3-nitropyridine 

Relevant academic research and scientific papers

Chemical development of the casein kinase i - Epsilon inhibitor: 3-(3-fluorophenyl)sulfanyl-1 H -pyrrolo[3,2- b pyridine-2-carboxylic acid amide

The development of a scalable process for 3-arylsulfanyl-1H-pyrrolo[3,2- bpyridine-2-carboxylic acid amides (1), potent casein kinase I inhibitors, is described. The rapid identification of suitable reaction conditions expedited the lab scale synthesis of drug substances for early toxicological evaluations. Further improvements were made to achieve a safe and cost-effective process to meet increasing demands for drug substances to support clinical studies. This paper describes the synthesis at multikilogram scale.

Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon

The present invention discloses and claims compounds of formula (I) as inhibitors of human casein kinase IF, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.